Ainult tellijatele

Autor: Violetta Riidas • 30. märts 2009

Ainult tellijatele

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

Paris, France; 24 February, 2009 – The European Commission has granted marketing authorisation for Servier’s Valdoxan® /Thymanax® (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes.

“There is still great scope for improved therapies to treat the devastating effects of depression”, said Professor Goodwin from Warneford Hospital, Oxford, United-Kingdom. “Valdoxan is an innovative, new approach to the management of depression that compares favourably to existing treatments. It has proven, sustained efficacy across a wide range of depressed patients, including those who are most severely depressed.”